His scientific interests lie mostly in Idiopathic pulmonary fibrosis, Immunology, Internal medicine, Pulmonary fibrosis and Interstitial lung disease. Toby M. Maher focuses mostly in the field of Idiopathic pulmonary fibrosis, narrowing it down to matters related to Vital capacity and, in some cases, Gastroenterology. In his research on the topic of Immunology, Microbiome, Kinase, Transforming growth factor beta and Lung injury is strongly related with Bronchoalveolar lavage.
Toby M. Maher usually deals with Internal medicine and limits it to topics linked to Placebo and Randomized controlled trial, Clinical endpoint and Surgery. In his work, Apoptosis, Protein kinase B and CpG site is strongly intertwined with Cancer research, which is a subfield of Pulmonary fibrosis. He has included themes like Spirometry and Pulmonary function testing in his FEV1/FVC ratio study.
Toby M. Maher focuses on Idiopathic pulmonary fibrosis, Internal medicine, Interstitial lung disease, FEV1/FVC ratio and Lung. His Idiopathic pulmonary fibrosis research includes elements of Vital capacity, Disease, Pathology and Immunology. Toby M. Maher combines subjects such as Idiopathic interstitial pneumonia and Respiratory system with his study of Pathology.
His Internal medicine research is multidisciplinary, incorporating elements of Gastroenterology and Placebo. He has researched Interstitial lung disease in several fields, including Clinical trial, Randomized controlled trial, Intensive care medicine, Connective tissue disease and Physical therapy. His studies deal with areas such as Spirometry, Surgery, Pulmonary function testing and Cardiology as well as FEV1/FVC ratio.
His primary areas of study are Internal medicine, Idiopathic pulmonary fibrosis, Nintedanib, Interstitial lung disease and Gastroenterology. In the field of Internal medicine, his study on FEV1/FVC ratio and Vital capacity overlaps with subjects such as In patient. His Idiopathic pulmonary fibrosis research entails a greater understanding of Lung.
His research integrates issues of Sildenafil, Subgroup analysis and Cardiology in his study of Nintedanib. Toby M. Maher combines subjects such as Clinical trial, MEDLINE, Intensive care medicine, Pulmonary rehabilitation and Pulmonary function testing with his study of Interstitial lung disease. His Gastroenterology study combines topics in areas such as Galectin-3, Bronchoscopy, Hazard ratio, Biomarker and Concomitant.
Toby M. Maher spends much of his time researching Internal medicine, Idiopathic pulmonary fibrosis, Lung, Interstitial lung disease and Placebo. His work in Internal medicine addresses subjects such as Gastroenterology, which are connected to disciplines such as Pathogenesis, Monocyte count, Prognostic biomarker and Single-nucleotide polymorphism. Toby M. Maher interconnects Exacerbation, Hypersensitivity pneumonitis, Fibrosis, Pulmonary fibrosis and Positron emission tomography in the investigation of issues within Idiopathic pulmonary fibrosis.
The concepts of his Lung study are interwoven with issues in Pharmacology, Respiratory system and Pathology. His Interstitial lung disease research is multidisciplinary, relying on both Allele, Allele frequency, Intensive care medicine, Pulmonary function testing and Genetic association. His work deals with themes such as Pharmacokinetics, Clinical endpoint and Tolerability, which intersect with Placebo.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Interstitial lung disease in systemic sclerosis: a simple staging system.
Nicole S. L. Goh;Sujal R. Desai;Srihari Veeraraghavan;David M. Hansell.
American Journal of Respiratory and Critical Care Medicine (2008)
Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report
Collard Hr;Ryerson Cj;Corte Tj;Jenkins G.
American Journal of Respiratory and Critical Care Medicine (2016)
Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis.
Tasha E. Fingerlin;Elissa Murphy;Weiming Zhang;Anna L. Peljto.
Nature Genetics (2013)
Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease.
Oliver Distler;Martina Gahlemann;Toby M Maher.
The New England Journal of Medicine (2019)
Idiopathic pulmonary fibrosis: multiple causes and multiple mechanisms?
T M Maher;A U Wells;G J Laurent.
European Respiratory Journal (2007)
The Role of Bacteria in the Pathogenesis and Progression of Idiopathic Pulmonary Fibrosis
Phillip L. Molyneaux;Michael J. Cox;Saffron A. G. Willis-Owen;Patrick Mallia.
American Journal of Respiratory and Critical Care Medicine (2014)
Pulmonary fibrosis secondary to COVID-19: a call to arms?
Paolo Spagnolo;Elisabetta Balestro;Stefano Aliberti;Stefano Aliberti;Elisabetta Cocconcelli.
The Lancet Respiratory Medicine (2020)
Increased local expression of coagulation factor X contributes to the fibrotic response in human and murine lung injury
Chris J. Scotton;Malvina A. Krupiczojc;Melanie Königshoff;Paul F. Mercer.
Journal of Clinical Investigation (2009)
Pleuroparenchymal fibroelastosis: a spectrum of histopathological and imaging phenotypes.
Taryn L. Reddy;Masaki Tominaga;David M. Hansell;Jan von der Thusen.
European Respiratory Journal (2012)
Rituximab in severe, treatment-refractory interstitial lung disease.
Gregory J. Keir;Toby M. Maher;Damien Ming;Reza Abdullah.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: